1 – 20 of 20
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
(
- Contribution to journal › Article
-
Mark
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
(
- Contribution to journal › Article
- 2022
-
Mark
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
- 2021
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease : A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
(
- Contribution to journal › Article
- 2020
-
Mark
Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
(
- Contribution to journal › Article
- 2019
-
Mark
Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease
(
- Contribution to journal › Article
- 2018
-
Mark
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease : a cohort study
(
- Contribution to journal › Article
-
Mark
Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders
(
- Contribution to journal › Article
- 2017
-
Mark
18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
In vivo retention of (18)F-AV-1451 in corticobasal syndrome
(
- Contribution to journal › Article
-
Mark
Tau pathology distribution in Alzheimer's disease corresponds differentially to cognition-relevant functional brain networks
(
- Contribution to journal › Article
-
Mark
Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology
(
- Contribution to journal › Article
-
Mark
Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease
(
- Contribution to journal › Article